Zatolmilast

N/A

Report date: 2023/09/28 14:39:46
NME

Base Information

Drug NameZatolmilast
Drug Alias NameBPN-14770
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodieterase 4 inhibitors
TargetsPhosphodieterase 4
Therapy Area/IndicationsJordan's syndromeDepressionRenal Insufficiency +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTetra
China Registration ClassN/A

Develop Information

Active CompaniesTetra Discovery Partners IncShionogi & Co Ltd
Inactive CompaniesNational Institute Of Mental Health (Nimh)
Active IndicationsJordan's syndromeRenal InsufficiencyFragile X Syndrome +[4] 
Inactive IndicationsDepressionAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A